Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming
More events are coming soon.
Prior

March 13, 2019 9:00 AM EDT
Barclays Global Healthcare Conference

March 11, 2019 12:00 PM EDT
Cowen and Company Health Care Conference

February 14, 2019 8:00 AM EST
Q4 2018 Incyte Corporation Earnings Conference Call

SEC Filings

Filing date Description Filing Group View

Official notification to shareholders of matters to be brought to a vote ("Proxy")

Proxy Filings

Statement of changes in beneficial ownership of securities

3,4,5

An amendment to a SC 13D filing

3,4,5

Investor Contacts

Michael Booth D.Phil
Vice President, Investor Relations
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Kwiecinski
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: lkwiecinski@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536